Sandoz Sees Aurobindo Deal Collapse As ‘Opportunity’
Termination Of $1bn Deal Will Allow Firm To ‘Optimize US Business’
Sandoz says closing the door on its proposed deal with Aurobindo will open up opportunities for the Novartis subsidiary to optimize its US business, as global sales for Sandoz shot up by around a tenth in the first quarter of 2020 on the back of a COVID-19 boost and a leap of almost a third in Biopharmaceuticals sales.
